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Abstract
Introduction: Surfactant protein D (SP-D) is a collectin with immuno-regulatory functions, which may depend on
oligomerization. Anti-microbial and anti-inflammatory properties have been attributed to multimeric SP-D variants,
while trimeric subunits per se have been suggested to enhance inflammation. Previously, we reported low
circulating SP-D in early rheumatoid arthritis (RA), and the present investigation aims to extend these data by serial
SP-D serum measurements, studies on synovial fluid, SP-D size distribution and genotyping in patients with early
RA.
Methods: One-hundred-and-sixty disease-modifying antirheumatic drug (DMARD) naïve RA patients with disease
duration less than six months were studied prospectively for four years (CIMESTRA (Ciclosporine, Methotrexate,
Steroid in RA) trial) including disease activity measures (C-reactive protein, joint counts and Health Assessment
Questionnaire (HAQ) score), autoantibodies, x-ray findings and SP-D. SP-D was quantified by enzyme-linked
immunosorbent assay (ELISA) and molecular size distribution was assessed by gel filtration chromatography.
Further, SP-D Met11Thr single nucleotide polymorphism (SNP) analysis was performed.
Results: Serum SP-D was significantly lower in RA patients at baseline compared with healthy controls (P < 0.001).
SP-D increased slightly during follow-up (P < 0.001), but was still subnormal at four years after adjustment for
confounders (P < 0.001). SP-D in synovial fluid was up to 2.5-fold lower than in serum. While multimeric variants
were detected in serum, SP-D in synovial fluid comprised trimeric subunits only. There were no significant
associations between genotype distribution and SP-D. Baseline SP-D was inversely associated to CRP and HAQ
score. A similar relationship was observed regarding temporal changes in SP-D and CRP (zero to four years). SP-D
was not associated to x-ray findings.
Conclusions: This study confirms that circulating SP-D is persistently subnormal in early and untreated RA despite
a favourable therapeutic response obtained during four years of follow-up. SP-D correlated negatively to disease
activity measures, but was not correlated with x-ray progression or SP-D genotype. These observations suggest that
SP-D is implicated in RA pathogenesis at the protein level. The exclusive presence of trimeric SP-D in affected
joints may contribute to the maintenance of joint inflammation.
Trial registration: (j.nr NCT00209859).
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Within recent years, search for innate immune system
abnormalities in rheumatoid arthritis (RA) has attracted
considerable attention [1]. Thus, low serum levels of
mannan-binding lectin (MBL) have been associated with
increased risk of early disease onset and severity of RA
[2,3]. Likewise, variant MBL alleles have been associated
with an unfavourable disease course [4,5]. Recently, we
reported that the serum level of another collectin, sur-
factant protein D (SP-D), is decreased in newly-diag-
nosed, untreated RA [6]. In that study comprising
45 DMARD naïve patients, systemic SP-D was not sig-
nificantly associated to conventional measures of disease
activity such as C-reactive protein and joint counts [6].
Collectins are pattern recognition molecules, which
preferentially bind to carbohydrate moieties expressed
on a variety of pathogens (pathogen associated molecu-
lar patterns (PAMPs)), thereby enhancing aggregation,
opsonisation or MBL-mediated complement activation
[7]. SP-D has a complex quaternary structure in which
monomers are assembled into tetramers forming dode-
camers or higher order multimers [8,9]. Multimeric SP-
D is suggested to have anti-microbial properties [10-13].
The function of natural trimeric subunit SP-D is not
known in detail, but it seems to be devoid of anti-
inflammatory activity [10-13]. SP-D is primarily synthe-
sized by the respiratory epithelium (type II epithelial
cells and Clara cells) [14,15], but is also expressed in a
variety of extra-pulmonary epithelia [16]. SP-D has been
detected in various body fluids including serum, synovial
fluid, lacrimal and broncho-alveolar lavage liquid
[17-22]. A common polymorphism in the SP-D gene on
chromosome 10, Met11Thr, resulting in either methio-
nine or threonine at residue 11, is a major determinant
for the serum concentration and multimerization of SP-
D [13,22]. The Thr11-variant is associated with reduced
oligomerization, reduced binding capacity of microbes
and low serum levels in healthy subjects [13].
The present investigation extends our previous obser-
vation by readdressing the possible association between
SP-D and the Met11Thr polymorphism in early,
untreated RA, and by studying the correlation between
SP-D and disease activity measures and radiographic
progression during a four-year interventional study on
DMARD naïve patients with RA of recent onset. In
addition, we compared the SP-D molecular size distribu-
tion in synovial fluid and corresponding sera.
Materials and methods
Patients and controls
One-hundred-and-sixty RA patients were included in
the multicenter, randomized, double-blinded, parallel-
group, placebo-controlled CIMESTRA trial [23,24].
Briefly, patients fulfilled the American College of Rheu-
matology 1987 revised criteria for RA [25]. Further, the
patients appeared with active disease less than six
months, less than or equal to two swollen joints at base-
line, and were aged 18 to 75 years [23,24]. Health
Assessment Questionnaire (HAQ score, 0 to 3) [26],
Visual Analogue Scale (0 to 10) (VAS pain, global and
doctor) and Disease Activity Score in 28 joints (DAS28)
[27] were calculated. Fourteen-hundred-and-seventy-six
healthy twin-individuals aged 18 to 67 years served as
controls [22]. The trial was approved by the local ethics
committee (j. nr M1959-98) and fulfilled the Declaration
of Helsinki and the International Conference on Harmo-
nisation 1996 revised guidelines for Good Clinical Prac-
tice (j.nr NCT00209859). Signed informed consent was
obtained from all study participants.
Treatment strategy
The treatment protocol compared methotrexate (MTX)
plus cyclosporine vs. MTX plus placebo. During the first
eight weeks patients were assessed fortnightly and every
four weeks thereafter. Subsequently, whenever synovitis
was present MTX dose was escalated by 2.5 mg from
7.5 mg/week to maximum 20 mg/week followed by a
stepwise cyclosporine/placebo-cyclosporine increment
(0.5 mg/kg) every four weeks from 2.5 mg/kg to maxi-
mum 4.0 mg/kg. In addition, intra-articular betametha-
sone (7 mg/l) was injected into swollen joints at any visit
(maximum four joints or 4 ml per visit). During the sec-
ond year, hydroxychloroquine (200 mg/day) was added
and cyclosporine/placebo was tapered to zero, while
MTX was continued [23,24]. During the open extension
study from three to four years the treatment strategy
continued to aim at tight synovitis control. Oral gluco-
corticoids were allowed in the open extension study.
Laboratory measures
Serum was obtained from routinely drawn non-fasting
blood samples collected between 08.00 a.m. to 2.00 p.m.
Samples were allowed to clot at room temperature fol-
lowed by centrifugation at 3,000 × g for 10 minutes.
Sera were stored at -80°C.
SP-D was measured at baseline, after two weeks, one
and six months, and after one, two, three and four years
using a five-layered sandwich ELISA as previously
described [19]. In controls, SP-D was only measured at
baseline. All analyses were done in duplicate and serial
samples from the same patient were analyzed simulta-
neously. The inter-assay coefficients of variation were
3.5 and 3.8% for low (367 ng/ml) and high (2,470 ng/
ml) quality controls, respectively, and the intra-assay
coefficients of variation were 1.7% for both quality con-
trols. C-reactive protein (CRP) (mg/l) and erythrocyte
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standard methods. IgM-rheumatoid factor (IgM-RF)
(cut-off level < 16 IU/ml) and anti-CCP (cut-off level <
24 U/ml) (Euro Diagnostica AB, Malmö, Sweden) were
measured by ELISA as previously described [28-30].
Radiographic analysis
Radiographs of hands, wrists, and forefeet were obtained
at baseline (n = 155), and annually thereafter. After four
years 137 radiographs were available, but only
133 patients had radiographs available at baseline and at
four years. Radiographs were scored according to Sharp-
van der Heijde by an independent senior radiologist
who was aware of the sequence of x-ray recordings [31].
The annual estimated progression rate in total Sharp-
van der Heijde Score (TSS), Joint Space Narrowing
score (JSN) and erosion score (ES) was calculated
according to disease duration and TSS, JSN and ES at
baseline for each patient [32]. Radiographic progression
was defined as the smallest detectable difference from
baseline (= one unit).
Synovial fluid
Corresponding serum and synovial fluid samples were
available from 20 RA patients with joint effusions before
treatment. Synovial fluid was collected by aseptic techni-
que before injection of glucocorticoid and stored at -80°C.
Before analysis, the samples were centrifuged 30 minutes
at 400 × g and subsequently the supernatant was incu-
bated four hour at 37°C with bovine testicular hyaluroni-
dase (Sigma H3884, St Louis, MO, USA) to reduce
viscosity (2 μl hyaluronidase (1 mg/ml in 0.2 M TRIS,
0.1 M sodium acetate, pH 7.0) to 300 μl synovial fluid).
Subsequently, they were centrifuged at 20.000 × g for 10
minutes at 4°C. The supernatant was assayed for SP-D by
ELISA. The possible trapping of SP-D in the synovial fluid
pellet was studied by incubating the pellet with ethylene-
diaminetetraacetic acid (EDTA) 0.52 M in a TRIS-buffered
saline (TBS) buffer (pH 7.4) at 37°C in 30 minutes fol-
lowed by centrifugation in four minutes at 20.000 × g and
4°C. A total of 50 μl of the resulting supernatant was
re-calcified with 60 μl of 1 M CaCl2, and pH was adjusted
to 7.9 by adding 28.5 μl 1 M TRIS pH 8.6 prior to analysis.
Gel filtration chromatography
Gel filtration chromatography was done on available
synovial fluid samples (n = 11) and corresponding sera.
Hyaluronidase-treated samples (200 μl) were applied to
an analytical Superose 6 column connected to a fast-
performance liquid chromatography system (former
Amersham Biosciences, now GE Healthcare, Uppsale,
Sweden) using TBS (pH 7.4) containing 10 mM EDTA
and 0.05% emulphogen as eluent at a flow rate of
24 ml/hr. Fractions of 0.2 ml were collected and
quantified by the SP-D ELISA. SP-D was eluted as two
structurally different forms with high and low molecular
weight (SP-D multimers (fraction 10 to 18) and SP-D
trimers (fraction 24 to 38)). Size chromatography on
healthy serum followed by SDS-PAGE and Western
blotting has yielded protein bands at > 250 kDa for mul-
timeric SP-D, and 90 kDa, 43 kDa and 40 kDa for tri-
meric SP-D [13,19].
Genotyping
G e n o m i cD N Aw a si s o l a t e df r o mE D T As t a b i l i z e d
whole blood. Applied Biosystems (Assay-by-design)
(Foster City, California, USA) designed primers and
probes for the non-synonymous substitutions of DNA-
bases of the SP-D gene resulting in the Met/Thr variant.
The genotyping procedure has been described previously
[13]. Human leucocyte antigen (HLA)-DRB1 genotyping
for shared epitope (SE) was performed by polymerase
chain reaction-based sequence-specific oligonucleotide
probing, as described elsewhere [33,34]. Herein, we
define the shared epitope as the presence of HLA-
DRB1*04 and/or HLADRB1*01 and/or HLADRB1*10.
Statistical analysis
All statistical analyses were conducted using STATA
version 9.2 (StataCorp, College Station, Texas, USA).
Comparisons between groups were done by Mann-
Whitney U-test or Fischer’s Exact Test, and if analysing
more than two groups, Kruskal-Wallis test was used.
Spearman Rank Correlation analysis was applied when
appropriate. Comparison between patients and controls
was performed using linear regression models, where
control twins were clustered in pairs. Linear regression
was also applied in the prospective analysis of SP-D in
RA patients, where repeated measurements in the indi-
vidual patient were clustered. We used logistic regres-
sion to assess whether baseline SP-D could predict
radiographic progression after four years with adjust-
ment for gender, age, smoking, anti-CCP and radio-
graphic status at baseline. Robust estimation of standard
error was calculated. To approximate a normal distribu-
tion, SP-D was logarithmically transformed when used
as continuous, dependent variable in linear regression
analyses.
One individual from each healthy twin pair was used
for genotype and allele frequency estimation. The geno-
type frequencies were tested for Hardy-Weinberg equili-
brium by (c
2-analysis. Comparisons of genotype and
allele frequencies in patients and controls were per-
formed by logistic regression with adjustment for gender
and age or by Fishers Exact test.
Since SP-D did not differ between treatment arms,
data from all RA patients were pooled. Analysis was by
intention-to treat (N = 142). Completers’ analysis was
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shown). Results are presented as median (95% confi-
dence interval) if not otherwise stated. P-values ≤ 0.05
and P ≤ 0.01 were considered significant with single and
multiple testings, respectively.
Results
RA patients and controls
Of 160 patients included, 61 (38%) did not complete the
four-year protocol. The reasons for drop-out were
adverse events (11), treatment failure (10), patients’
request (13) and other (27). Fifty-six (35%) left the study
during the first two years. Patients who dropped out did
not differ from completers with regard to demographic
and clinical variables at baseline (data not shown). At
baseline one patient had serum SP-D of 8,106 ng/ml.
This patient subsequently developed severe pulmonary
fibrosis and was excluded from the statistical analyses.
The demographic characteristics of the RA patients at
baseline and the control population are shown in
Table 1. Among the 142 patients included in the inten-
tion-to-treat analyses, all data for composite disease
activity measures were available in 134 individuals.
Seventy-eight percent, 66% and 69% had achieved
ACR50, ACR70 and DAS28 < 2.6 after four years.
Including patients with radiographs available at both
baseline and after four years (N = 133), 53%, 23% and
49% progressed radiographically according to TSS, JSN
and ES score, respectively. Of note, however, radio-
graphic progression at four-year follow-up was small in
terms of Sharp/van der Heijde units (median (iqr): TSS
2 (0 to 7) to 5 (0 to 11), JSN 0 (0 to 2) to 0 (0 to 4) and
ES 2 (0 to 5) to 3 (0 to 8)).
Serum SP-D in RA
Baseline SP-D in RA patients was 693 ng/ml (649; 770)
vs. 913 ng/ml (879; 945) in controls (P < 0.001). This
difference persisted after adjustment for age, gender and
current smoking status (P < 0.001) and was also present
at four years after adjustment for confounders (P <
0.001). Compared to baseline, SP-D had increased in RA
patients at four years (893 ng/ml [810; 1013] vs. 693 ng/
ml [649; 770], P < 0.001) even when adjusting for gen-
der, age and smoking status (p < 0.001). However, at
four years, SP-D was still lower in RA patients as com-
pared to controls with adjustment for confounders (P <
0.001). There was no significant correlation between age
and SP-D in the RA population (rho = 0.06, P =0 . 4 2 ) .
Likewise, there was no significant gender difference
among RA patients. In contrast, SP-D increased signifi-
cantly with age in healthy subjects (rho = 0.21, P <
0.001), and control males had significantly higher levels
of SP-D compared to females (Table 2). Both RA and
control smokers had significantly higher SP-D than
non-smokers (Table 2). Disease activity markers and
HAQ score were inversely correlated to SP-D at baseline
(CRP: rho = -0.30, P < 0.001, DAS28: rho = -0.23, P =
0.003 and HAQ: rho = -0.21, P = 0.008). No significant
difference in SP-D at baseline was observed between
patients with respect to anti-CCP, IgM-RF status or any
SE present (P =0 . 5 0 ,P = 0.14, and P = 0.24, respec-
tively). Furthermore, SP-D did not differ between smok-
ing SE positive vs. non-smoking SE positive patients (P
=0 . 1 3 ) .
Table 1 Demographic characteristics of RA patients at baseline and healthy controls
Characteristics RA patients (N = 160) Controls (N = 1476) P-value
Gender f/m (%women) 107/53 (67%) 761/715 (52%) P < 0.001
Age in years 53(42 to 63) 38 (29 to 46) P < 0.001
Current smokers (%) 57 (36%) 482 (33%) P = 0.42
Disease duration (months) 3.5 (2.7 to 5.0) - -
IgM-rheumatoid factor positive (%) 103 (65%) - -
Anti-CCP positive (%) 93 (58%) - -
Any SE present (%) 116 (73%) - -
Median (inter-quartile range)
Comparison between groups was carried out using Mann-Whitney U-test and Fischers Exact test
Anti-CCP, antibodies against cyclic citrullinated peptides; SE, shared epitopes; RA, rheumatoid arthritis
Table 2 Baseline surfactant protein D in serum (ng/ml) in
smokers and non-smokers and according to gender in
patients and controls
RA-patients Controls
Men 760 (665;1059) 967 (921;1024)
Women 674 (613;759) 852 (818;902)
P-value* 0.09 < 0.001
Smokers 850 (686;1014)
(n = 57)
1187 (1099;1293) (n = 482)
Non-smokers 671 (604;738)
(n = 101)
827 (802;852) (n = 991)
P-value* 0.03 < 0.001
Median [95% CI], *Mann-Whitney U-test
RA, rheumatoid arthritis
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related inversely to the SP-D change (ΔCRP vs. ΔSP-D,
rho = -0.39 and P < 0.001). We found no association
between SP-D and radiographic data including estimated
annual progression rate (data not shown). Baseline SP-D
did not predict radiographic progression (Total Sharp
score) at four years (P = 0.46)
SP-D in synovial fluid and corresponding sera
Synovial fluid was obtained from 20 patients at baseline.
Median SP-D in synovial fluid was 275 ng/ml (221; 299).
SP-D in corresponding sera was 678 ng/ml (592; 829). SP-
D in synovial fluid and serum levels correlated significantly
(rho = 0.69, P < 0.001), Figure 1. Synovial fluid SP-D was
not significantly associated with sex, age, CRP, autoantibo-
dies, any SE or radiographic findings (data not shown).
There was no detectable SP-D in the debris enriched pel-
lets resulting from centrifugation of the synovial fluid.
Results from the gel filtration chromatography are out-
lined in Figure 2. Multimeric SP-D was barely detectable
in synovial fluid as compared to serum, where both multi-
meric and trimeric molecular variant SP-D (trimeric subu-
nits) were detected.
Genetic SP-D variation in RA
The Met11Thr polymorphism was in Hardy-Weinberg
equilibrium in both RA and controls (data not shown).
The distribution of genotypes and allele frequencies is
presented in Table 4. When adjusting for gender and
age, there was no overrepresentation of Thr11Thr in RA
patients as compared with controls (Table 3). Circulat-
ing SP-D did not differ between genotypes in RA
patients, whereas healthy individuals with the Thr11Thr
genotype appeared with the lowest level as previously
reported [22]. The genotypes were not associated with
specific disease features including DAS28, CRP, joint
counts, auto-antibodies, HAQ or x-ray findings (data
not shown). The Met11Thr allelic variation could
neither predict x-ray progression nor disease activity
outcome after four years and the size distribution of SP-
D in synovial fluid did not differ between genotypes
(data not shown).
Discussion
Based on the structural similarity between SP-D and
MBL and our preliminary report on low circulating SP-
D in RA [6], this investigation was conducted to study
t h ep o s s i b l er o l eo fS P - Da sd i s e a s em o d i f i e ri nR A .
While confirming that SP-D in serum is significantly
decreased in newly-diagnosed, untreated RA sufferers,
we also found an inverse correlation between SP-D and
measures of disease activity at baseline. Although SP-D
increased significantly during follow-up, it remained
subnormal at four years.
The cause of low SP-D in RA is uncertain and differ-
ent mechanisms may be involved. Altered SP-D
Figure 1 Scatter plot of SP-D in serum and synovial fluid at baseline (n = 20). Fitted values are depicted by the line. SP-D, surfactant
protein D.
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considered. Thus, in healthy subjects the Thr11-variant
is associated with low SP-D in the circulation [22].
In the previous study by Hoegh et al [6], the Thr11
variant tended to be overrepresented in RA patients as
compared to controls. This trend was not confirmed in
the present study. Thus, a clear genetic contribution to
low SP-D in RA cannot be identified in this study. How-
ever, a possible genetic contribution to low SP-D in RA
cannot be completely disregarded from this study due to
the limited sample size. Moreover, it should be borne in
mind, that focusing at only one polymorphism in the
analysis of gene patterns and serum SP-D, may underes-
timate the significance of a genetic association, which is
better represented by haplotype blocks [35].
Decreased SP-D in RA could be attributable to
increased clearance from the circulation, for example, by
deposition in inflamed tissues or complex formation
with, for example, microbial or cellular waste [36,37].
Thus, cells undergoing apoptosis express auto-antigens,
which may lead to auto-antibody formation [38]. Both
in vitro and in vivo experiments have indicated that
Figure 2 Size exclusion chromatography of SP-D in serum and synovial fluid. Mean curves of 11 corresponding serum and synovial fluid
samples. SP-D was eluted as two structurally different forms (SP-D multimers (fraction 10 to 18) and SP-D trimers (fraction 24 to 38)). SP-D,
surfactant protein D.
Table 3 Distribution of the SP-D Met11Thr genotype and allele frequencies and corresponding SP-D serum levels
(median (95% CI))
N(%) of RA patients SP-D ng/ml*
RA patients
N(%) of controls SP-D ng/ml*
Controls
P-value** Odds ratio***
Genotype:
Met11/Met11 41 (27.3) 724 (636; 1,123) 152 (35.8) 1,081 (996; 1,252) P = 0.16 1.0 (ref)
Thr11/Thr11 27 (18.0) 750 (603; 834) 77 (18.1) 896 (788; 955) 1.3 (0.73; 2.4)
Met11/Thr11 82 (54.7) 660 (563; 761) 196 (46.1) 925 (845;1,023) 1.6 (0.97; 2.6)
Allele:
Met11 164 (54.7) 500 (58.8) P = 0.22 1.0 (ref)
Thr11 136 (45.3) 350 (41.2) 1.2 (0.9;1.6)
* Kruskal-Wallis test: RA patients: P = 0.13 and controls: P = 0.0023
** Distribution, P-value calculated using Fishers’ Exact test
*** Odds ratio (95% CI) calculated using logistic regression with health status as the dependent variable and genotype/allele, gender and age as independent
variables.
CI, confidence interval; SP-D, surfactant protein -D; RA, rheumatoid arthritis; Ref, reference
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macrophages, thereby reducing anti-dsDNA antibody
generation [36,39,40]. Such a scavenger mechanism for
SP-D in RA is supported by the inverse association
between SP-D and disease activity measures and by the
gradual SP-D increase during treatment. The inverse
association of SP-D and inflammatory signs and the lack
of association between SP-D and erosive progression
after four years indicate, that subnormal SP-D is primar-
ily linked to systemic inflammation. According to this,
depressed systemic SP-D may contribute to persistent
low-grade, subclinical joint inflammation as evidenced
by MRI and ultrasonic findings [41,42].
In order to further elucidate the possible role of SP-D in
joint inflammation, we quantified SP-D in paired serum
and synovial samples and studied the molecular size distri-
bution in serum and synovial fluid. We found a SP-D
serum:synovial fluid ratio at approximately 3:1, which indi-
cates that SP-D reaches the joint cavity by diffusion (bulk
flow) [43]. The diffusion capacity for proteins across the
synovial membrane in rheumatoid arthritis depends on
the degree of synovial inflammation and molecular size
[43-45]. While both multimeric and trimeric subunit SP-D
were present in serum, only trimeric forms could be
demonstrated in synovial fluid. This further supports that
diffusion is the major source of SP-D in the joint cavity
although local degradation of the molecule cannot be
excluded. Knowledge about the biologic properties of tri-
meric SP-D is incomplete. However, previous studies have
indicated that trimers interact preferentially with specific
microbes, microbial compounds or endogenous lipopro-
teins [19,46] implying that trimeric SP-D may possess spe-
cialized functions as compared with multimeric SP-D.
Previously, Gardai et al proposed a model for dual inflam-
matory activity of SP-D. In the absence of microbial
ligands and cell debris, binding of SP-D to macrophages
by the CRD region was suggested to be anti-inflammatory
by blocking p38 mitogen-activated protein kinases (p38
MAPK) [47]. By contrast, binding of microbial constitu-
ents to the CRD region of SP-D would lead to a pro-
inflammatory response [47]. Recently, it was shown that
posttranslational nitrosylation of cystein residues in the
N-terminus of SP-D (SNO-SP-D) caused by inflammation
resulted in disruption of multimeric SP-D into nitrosylated
trimers. This modified trimeric SP-D variant would subse-
quently initiate a pro-inflammatory response via calreticu-
lin/CD91 receptor interaction and activate p38 MAPK
[48]. Inflammatory signalling resulting in p38 phosphory-
lation has been identified as an important determinant of
synovitis severity [49]. Thus, in theory the dominance of
low molecular weight SP-D in synovial fluid observed in
the present study may contribute to the maintenance of
joint inflammation in RA.
SP-D in serum is suggested to originate primarily from
pulmonary leakage [50]. It has previously been demon-
strated that smoking increases SP-D in serum [22]. Our
findings demonstrate that this also applies to RA
patients implying that smoking is a confounder that
should be corrected for in the statistical analysis. It has
been hypothesized that anti-CCP antibodies can be trig-
gered by smoking through citrullination of lung proteins
in SE carriers [51]. We found no correlation between
circulating SP-D and SE status in smoking and non-
smoking RA patients.
When interpreting the present results, the relatively
large number of drop-outs should be considered. How-
ever, there was no difference with respect to baseline
characteristics between completers and non-completers
and the intention to treat analysis included a large
majority of the cohort.
SP-D did not correlate to age in RA patients, but
tended to be higher in males compared to females. By
contrast, SP-D was significantly higher in control males
as compared to females, and SP-D correlated positively
with age. This disparity may be due to the different
sizes of the RA and control populations and the relative
overrepresentation of females in the RA cohort. Due to
the difference in age distribution in the two populations
and rather few controls aged above 50 years we used
logistic regression with adjustment for gender and age
instead of regular frequency matching in comparisons
between controls and patients.
Conclusions
Circulating SP-D is subnormal at disease onset and after
four years treatment in RA. There were no SP-D
Met11Thr associations with RA disease activity or sub-
normal SP-D. While SP-D did not correlate with x-ray
progression, we found an inverse association between
SP-D and disease activity markers suggesting that low
systemic SP-D is involved in the initiation or mainte-
nance of synovitis. Whereas both multimeric and tri-
meric SP-D variants occurred in serum, only low
molecular forms were detected in synovial fluid where it
may contribute to joint inflammation. Overall, this study
suggests that SP-D is implicated in RA pathogenesis at
the protein level.
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polymorphism; SP-D: surfactant protein -D; TBS: TRIS-buffered saline; TSS:
total Sharp-van der Heijde Score; VAS: visual analogue scale.
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